Aqua Bio Technology（3FZ0）株式概要アクア・バイオテクノロジー社は、ノルウェーで化粧品原料の製造・販売を行っている。 詳細3FZ0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析収益が 100 万ドル未満 ( NOK8M )過去5年間で収益は年間61.6%減少しました。 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( €7M )+1 さらなるリスクすべてのリスクチェックを見る3FZ0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.45104.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-337m107m2016201920222025202620282031Revenue NOK 87.9mEarnings NOK 8.2mAdvancedSet Fair ValueView all narrativesAqua Bio Technology ASA 競合他社Bio-GateSymbol: DB:BIG1Market cap: €7.7mBRAIN BiotechSymbol: XTRA:BNNMarket cap: €70.3mNabaltecSymbol: XTRA:NTGMarket cap: €93.3mH&R GmbH KGaASymbol: XTRA:2HRAMarket cap: €174.9m価格と性能株価の高値、安値、推移の概要Aqua Bio Technology過去の株価現在の株価NOK 0.4552週高値NOK 9.7052週安値NOK 0.01ベータ0.0961ヶ月の変化-21.78%3ヶ月変化-10.20%1年変化-77.32%3年間の変化-97.29%5年間の変化n/aIPOからの変化-99.48%最新ニュースNew Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights OfferingNew Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesNew Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights OfferingNew Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (€4.54m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (€7.30m market cap, or US$8.54m).お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offeringお知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct ListingNew Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.87m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (€6.87m market cap, or US$7.43m).お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€19.8m market cap, or US$20.6m).New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€17.6m market cap, or US$18.3m).New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€16.2m market cap, or US$17.3m).お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").New Risk • Aug 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€20.9m market cap, or US$23.4m).New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€19.9m market cap, or US$21.5m).お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€21.6m market cap, or US$23.7m).お知らせ • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listingお知らせ • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€17.2m market cap, or US$18.3m).お知らせ • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$675k). Market cap is less than US$10m (€7.40m market cap, or US$8.03m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).お知らせ • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.お知らせ • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.お知らせ • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.お知らせ • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.お知らせ • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Jul 29Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022.お知らせ • Jun 30Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 12Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UKAqua Bio Technology ASA announced that Hydrafacial has now launched Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL) in the UK. The kit includes the RestorseaTM Lip Serum, to be administered during the lip treatment, and the Lip Elixir gloss as a hydrator and natural exfoliator to be applied post-treatment. Restorsea has built its company and business idea on Aquabeautine XL and has through 2021 had increasing orders of Aquabeautine XL which fit in-line with its expanded distribution. Restorsea is distributing products, own and out-licensed and all basen on ABT's hatching fluid Ingredient Aquabeautine XL, in South Korea, US, Brazil, and in approx 130 doctors offices in the US (Restorsea-branded products) as well as distribution through Nasdaq-listed Hydrafacial in the US and UK (Restorsea-developed products for Hydrafacial Perk) and in the US through Nasdaq-listed LifeMD (private label).Board Change • Sep 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元3FZ0DE ChemicalsDE 市場7D-1.8%3.0%-0.6%1Y-77.3%3.7%0.2%株主還元を見る業界別リターン: 3FZ0過去 1 年間で3.7 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: 3FZ0は、過去 1 年間で0.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 3FZ0's price volatile compared to industry and market?3FZ0 volatility3FZ0 Average Weekly Movement1,389.3%Chemicals Industry Average Movement6.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.1%10% least volatile stocks in DE Market2.7%安定した株価: 3FZ0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 3FZ0の 週次ボラティリティ は、過去 1 年間で648%から1389%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト200037Kristian Flatenaquabiotechnology.comアクアバイオテクノロジー社は、ノルウェーで化粧品原料の製造・販売を行っている。同社は、スキンケア製品用の独自成分であるアクアビューティンXLと、化粧品用の抗酸化・ビタミン強化スピルリナであるスピルリサットを提供している。インターネット、店舗、スキンケアクリニックを通じて製品を販売している。アクア・バイオ・テクノロジー社は2000年に設立され、ノルウェーのオスロに本社を置いている。もっと見るAqua Bio Technology ASA 基礎のまとめAqua Bio Technology の収益と売上を時価総額と比較するとどうか。3FZ0 基礎統計学時価総額€7.14m収益（TTM）-€2.29m売上高(TTM)€699.06k10.2xP/Sレシオ-3.1xPER（株価収益率3FZ0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計3FZ0 損益計算書（TTM）収益NOK 7.53m売上原価NOK 1.11m売上総利益NOK 6.42mその他の費用NOK 31.05m収益-NOK 24.64m直近の収益報告Dec 31, 2025次回決算日Aug 14, 2026一株当たり利益（EPS）-1.58グロス・マージン85.22%純利益率-327.05%有利子負債／自己資本比率-22,240.7%3FZ0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/14 15:59終値2026/05/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aqua Bio Technology ASA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Tomas SkeivysNorne Securities AS
New Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).
お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).
New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).
Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.
New Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (633% average daily change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (€7.17m market cap, or US$8.40m).
お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.56m market cap, or US$7.69m).
New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (€6.71m market cap, or US$7.81m).
Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 18 percentage points per year, which is a significant difference in performance.
New Risk • Nov 30New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (€4.54m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).
お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.
お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (€7.30m market cap, or US$8.54m).
お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.
お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offering
お知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct Listing
New Risk • Mar 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.87m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (€6.87m market cap, or US$7.43m).
お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.
お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.
お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€19.8m market cap, or US$20.6m).
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€17.6m market cap, or US$18.3m).
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (€16.2m market cap, or US$17.3m).
お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.
お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").
New Risk • Aug 24New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€20.9m market cap, or US$23.4m).
New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€19.9m market cap, or US$21.5m).
お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€21.6m market cap, or US$23.7m).
お知らせ • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (€17.2m market cap, or US$18.3m).
お知らせ • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.
New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$675k). Market cap is less than US$10m (€7.40m market cap, or US$8.03m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).
お知らせ • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.
お知らせ • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.
お知らせ • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.
お知らせ • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.
お知らせ • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Jul 29Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022.
お知らせ • Jun 30Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As on June 28, 2022. The purchase price will be based on a earn-out based on a multiple of Cosmed's result before tax for each of the financial year 2022, 2023, 2024 and 2025. The majority of the purchase price (appr. 3/4) will be used to subscribe for new shares in ABT at a subscription price of NOK 8,20 following Cosmed's adoption of its annual accounts for 2022-2025. The transaction will be completed following a satisfactory due diligence and ABT's board approval. The Parties shall finalize a share purchase agreement within 31 July 2022.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 12Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UKAqua Bio Technology ASA announced that Hydrafacial has now launched Restorsea Lip Fix Kit which is based on ABT's hatching fluid ingredient (Aquabeautine XL) in the UK. The kit includes the RestorseaTM Lip Serum, to be administered during the lip treatment, and the Lip Elixir gloss as a hydrator and natural exfoliator to be applied post-treatment. Restorsea has built its company and business idea on Aquabeautine XL and has through 2021 had increasing orders of Aquabeautine XL which fit in-line with its expanded distribution. Restorsea is distributing products, own and out-licensed and all basen on ABT's hatching fluid Ingredient Aquabeautine XL, in South Korea, US, Brazil, and in approx 130 doctors offices in the US (Restorsea-branded products) as well as distribution through Nasdaq-listed Hydrafacial in the US and UK (Restorsea-developed products for Hydrafacial Perk) and in the US through Nasdaq-listed LifeMD (private label).
Board Change • Sep 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
